search
Back to results

Durvalumab and Tremelimumab in Combination With Either Y-90 SIRT or DEB-TACE for Intermediate Stage HCC

Primary Purpose

Hepatocellular Carcinoma Non-resectable, HCC

Status
Recruiting
Phase
Phase 2
Locations
Germany
Study Type
Interventional
Intervention
Tremelimumab
Durvalumab
Y-90 SIRT
DEB-TACE
Sponsored by
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hepatocellular Carcinoma Non-resectable focused on measuring hepatocellular carcinoma, intermediate stage HCC, SIRT, TACE, Durvalumab, Tremelimumab

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Capable of giving written informed consent and any locally-required authorization (EU Data Privacy Directive in the EU) obtained from the subject prior to performing any protocol-related procedures, including screening evaluations.
  2. Age ≥ 18 years at time of study entry.
  3. Body weight > 30 kg.
  4. Multinodular or large, solitary HCC, not eligible for resection or local ablation.
  5. Histologically confirmed diagnosis of HCC.
  6. Scheduled to receive locoregional therapy as standard of care.
  7. At least one measurable site of disease as defined by RECIST 1.1criteria with spiral CT scan or MRI.
  8. No prior systemic anti-cancer therapy.
  9. Child-Pugh A.
  10. Performance status (PS) ≤ 1 (ECOG scale).
  11. Life expectancy of at least 12 weeks.
  12. Adequate blood count, liver-enzymes, and renal function:

    • Hemoglobin ≥ 9.0 g/dL, absolute neutrophil count ANC ≥1.5 (or 1.0) x (> 1500 per mm3), platelets ≥100 (or 75) x 109/L (>75,000 per mm3);
    • Serum bilirubin ≤1.5 x institutional upper limit of normal (ULN);
    • AST (SGOT), ALT (SGPT) ≤ 2.5 x institutional ULN unless liver metastases are present, in which case it must be ≤5x ULN;
    • International normalized ratio (INR) ≤ 1.25.
  13. Albumin ≥ 31 g/dL.
  14. Measured creatinine clearance (CL) >40 mL/min or Calculated creatinine clearance CL>40 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance.
  15. Female patients with reproductive potential must have a negative urine or serum pregnancy test within 7 days prior to start of trial and must use two effective forms of contraception if sexually active.
  16. Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year. Men receiving IMP and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 7 months after the last dose of investigational products (durvalumab and tremelimumab). Women who are not of childbearing potential (i.e. who are postmenopausal or surgically sterile) as well as azoospermic men do not require contraception).
  17. If patient has concurrent Hepatitis B virus (HBV) or Hepatitis C virus (HCV) infection, meets the following criteria:

    • Patients with HBV or HCV infection should be monitored for viral levels during study participation;
    • Patients with detectable hepatitis B surface antigen (HBsAg) or detectable HBV DNA should have HBV DNA < 100 IU/ml and should be managed per local treatment guidelines. Controlled (treated) hepatitis B subjects will be allowed if they started treatment at the time point of enrollment into the study by the latest and treatment is continued during study participation and for ≥ 6 months after end of study treatment;
    • HCV patients with advanced HCC are mostly not treated for their HCV infection. However, patients treated for HCV are considered suitable for inclusion if antiviral therapy has been completed prior to first administration of study drug.
  18. Subject is willing and able to comply with the protocol for the duration of the study including

Exclusion Criteria:

  1. Diffuse HCC or presence of vascular invasion or extrahepatic spread with the following exception:

    o Invasion of a segmental portal vein or hepatic veins.

  2. Patients with advanced liver disease as defined below:

    o liver cirrhosis with stage Child Pugh B and C.

  3. Any contraindications for hepatic embolization procedures:

    • Known hepatofugal blood flow;
    • Known porto-systemic shunt;
    • Impaired clotting test (platelet count < 70 Thsd/L, INR > 1.25);
    • Renal failure/insufficiency requiring hemo-or peritoneal dialysis;
    • Known severe atheromatosis;
    • Total thrombosis or total invasion of the main branch of the portal vein.
  4. Locoregional therapies ongoing or completed < 4 weeks prior to the baseline scan.
  5. History of cardiac disease:

    • Congestive heart failure > New York Heart Association (NYHA) class 2;
    • Active coronary artery disease (CAD) (myocardial infarction ≥ 6 months prior to study entry is allowed);
    • Cardiac arrhythmias (Grade > 2 NCI-CTCAE Version 5.0) which are poorly controlled with anti-arrhythmic therapy or requiring pace maker;
    • Uncontrolled hypertension;
    • Clinically significant gastrointestinal bleeding within 4 weeks prior to start of study drug.
  6. Thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within the 6 months prior to the first dose of study drug with the exception of thrombosis of a segmental portal vein.
  7. Prior, systemic anti-cancer therapy, radiotherapy administered < 4 weeks prior to study entry, endocrine- or immunotherapy or use of other investigational agents.
  8. Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab or tremelimumab. The following are exceptions to this criterion:

    • Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection)
    • Systemic corticosteroids at physiologic doses not to exceed <<10 mg/day>> of prednisone or its equivalent
    • Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)
  9. Receipt of live attenuated vaccine within 30 days prior to the first dose of IP. Note: Patients, if enrolled, should not receive live vaccine whilst receiving IP and up to 30 days after the last dose of IP.
  10. Major surgery within 4 weeks of starting the study and patients must have recovered from effects of major surgery.
  11. Patients with second primary cancer, except adequately treated basal skin cancer or carcinoma in-situ of the cervix, unless curatively treated and disease-free for 3 years or longer.
  12. Any co-existing medical condition that in the investigator's judgement will substantially increase the risk associated with the patient's participation in the study.
  13. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent
  14. Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C, Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA
  15. History of allogenic organ transplantation.
  16. Psychiatric disorders or altered mental status precluding understanding of the informed consent process and/or compliance with the study protocol.
  17. Symptomatic brain metastases. A scan to confirm the absence of brain metastases is required in the presence of corresponding symptoms.
  18. Pregnant or breast-feeding women.
  19. Immunocompromised patients, e.g. patients who are known to be serologically positive for human immunodeficiency virus (HIV).
  20. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc.]). The following are exceptions to this criterion:

    • Patients with vitiligo or alopecia
    • Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement
    • Any chronic skin condition that does not require systemic therapy
    • Patients without active disease in the last 5 years may be included but only after consultation with the study physician
    • Patients with celiac disease controlled by diet alone
  21. Known allergy or hypersensitivity to any of the IMPs or any of the constituents of the product.
  22. Is currently participating or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.
  23. Patient who has been incarcerated or involuntarily

Sites / Locations

  • Universitätsklinikum BonnRecruiting
  • Universitätsklinikum EssenRecruiting
  • Universitätsklinikum FreiburgRecruiting
  • Medizinische Hochschule HannoverRecruiting
  • Universitätsklinikum JenaRecruiting
  • Universitätsklinikum KölnRecruiting
  • Universtitätsklinikum Schleswig-HolsteinRecruiting
  • Klinikum rechts der Isar der Technischen Universität MünchenRecruiting
  • München Klinik BogenhausenRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

SIRT (Arm A)

TACE (Arm B)

Arm Description

Y-90 SIRT + Tremelimumab + Durvalumab

DEB-TACE + Tremelimumab + Durvalumab

Outcomes

Primary Outcome Measures

Objective response rate (ORR) [according to RECIST 1.1] at 6 months.
Proportion of allocated subjects with best response of complete or partial response

Secondary Outcome Measures

Progression free survival (PFS)
Time from the date of randomization to the date of first observed disease progression (investigator assessment according to RECIST 1.1) or death from any cause.
Overall survival (OS)
Overall survival will be determined as time from the date of treatment allocation to the date of death.
Treatment related SAEs
Treatment related serious adverse events rate (SAE) will be determined. All observed toxicities and side effects will be graded according to NCI CTCAE v5.0 for all patients and the degree of association of each with the study treatment assessed and summarized.
Overall response rate (ORR) as best overall response (BOR) during therapy
ORR as BOR during therapy will be defined as the proportion of allocated subjects with best response of complete or partial response from date of randomization until disease progression or death from any cause occurs.
Overall response rate (ORR) at 6 months
ORR at 6 months for patients who received single treatment of TACE/SIRT
Quality of Life (QoL)
Quality of life will be assessed by the European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC QLQ-C30 questionnaire) and will be evaluated based on the EORTC QLQ-C30 scoring manual in its most current version at time of data analysis.

Full Information

First Posted
August 4, 2020
Last Updated
August 29, 2023
Sponsor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Collaborators
AstraZeneca, Hannover Medical School
search

1. Study Identification

Unique Protocol Identification Number
NCT04522544
Brief Title
Durvalumab and Tremelimumab in Combination With Either Y-90 SIRT or DEB-TACE for Intermediate Stage HCC
Official Title
A Phase II Study of Immunotherapy With Durvalumab (MEDI4736) and Tremelimumab in Combination With Either Y-90 SIRT or TACE for Intermediate Stage HCC With Pick-the-winner Design
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 15, 2020 (Actual)
Primary Completion Date
March 31, 2025 (Anticipated)
Study Completion Date
September 30, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Collaborators
AstraZeneca, Hannover Medical School

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
A Phase II study of immunotherapy with Durvalumab (MEDI4736) and Tremelimumab in combination with either Y-90 SIRT or DEB-TACE for intermediate stage HCC with pick-the-winner design
Detailed Description
The IMMUWIN phase II will test the safety and anti-tumor efficacy of the combination of Durvalumab and Tremelimumab with either Y-90 SIRT or DEB-TACE. Patients will be randomized into two experimental arms, one receiving SIRT + Durvalumab + Tremelimumab, the other arm receiving TACE + Durvalumab + Tremelimumab. It will be determined whether the combination of immunotherapy with SIRT or TACE is more promising.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hepatocellular Carcinoma Non-resectable, HCC
Keywords
hepatocellular carcinoma, intermediate stage HCC, SIRT, TACE, Durvalumab, Tremelimumab

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
55 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
SIRT (Arm A)
Arm Type
Experimental
Arm Description
Y-90 SIRT + Tremelimumab + Durvalumab
Arm Title
TACE (Arm B)
Arm Type
Experimental
Arm Description
DEB-TACE + Tremelimumab + Durvalumab
Intervention Type
Drug
Intervention Name(s)
Tremelimumab
Intervention Description
300 mg Tremelimumab C1D1
Intervention Type
Drug
Intervention Name(s)
Durvalumab
Intervention Description
1500 mg Durvalumab C1D1 + Q4W (max. 13 cycles)
Intervention Type
Procedure
Intervention Name(s)
Y-90 SIRT
Intervention Description
Locoregional therapy will be performed as a standard-of-care procedure
Intervention Type
Procedure
Intervention Name(s)
DEB-TACE
Intervention Description
Locoregional therapy will be performed as a standard-of-care procedure
Primary Outcome Measure Information:
Title
Objective response rate (ORR) [according to RECIST 1.1] at 6 months.
Description
Proportion of allocated subjects with best response of complete or partial response
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Progression free survival (PFS)
Description
Time from the date of randomization to the date of first observed disease progression (investigator assessment according to RECIST 1.1) or death from any cause.
Time Frame
Time from the date of randomization to the date of first observed disease progression or death (approx. 42 months)
Title
Overall survival (OS)
Description
Overall survival will be determined as time from the date of treatment allocation to the date of death.
Time Frame
From the date of treatment Date of enrollment until date of death if applicable (up to 42 months until Study Closure)
Title
Treatment related SAEs
Description
Treatment related serious adverse events rate (SAE) will be determined. All observed toxicities and side effects will be graded according to NCI CTCAE v5.0 for all patients and the degree of association of each with the study treatment assessed and summarized.
Time Frame
From first patient included until study closure (approx. 42 months after First Patient Included)
Title
Overall response rate (ORR) as best overall response (BOR) during therapy
Description
ORR as BOR during therapy will be defined as the proportion of allocated subjects with best response of complete or partial response from date of randomization until disease progression or death from any cause occurs.
Time Frame
13 months
Title
Overall response rate (ORR) at 6 months
Description
ORR at 6 months for patients who received single treatment of TACE/SIRT
Time Frame
6 months
Title
Quality of Life (QoL)
Description
Quality of life will be assessed by the European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC QLQ-C30 questionnaire) and will be evaluated based on the EORTC QLQ-C30 scoring manual in its most current version at time of data analysis.
Time Frame
24 months
Other Pre-specified Outcome Measures:
Title
Translational research
Description
Exploratory: Correlation analysis between selected molecular parameters and clinical data to identify molecular biomarkers predictive for outcome are not fully defined at the time this protocol is written. The optional translational research program will consider the latest research data available at the time of analysis. Analysis might comprise (but is not limited to) staining for PD-L1 protein expression on tumor cells using the commercially available IVD Kits (22C3 pharmDx assay, DAKO North America) and lymphocytes, testing for expression of PD-1, PD-L1 and PD-L2, Immune cell infiltrates (IGHM, CD3, CD8, FOXP3, CD68, CD205), Chemokines (CXCL9. CXCL10, CXCL13) and invasion markers (MMP7, MMP9) and assessing circulating nucleic acids and tumor specific transcripts.
Time Frame
3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Capable of giving written informed consent and any locally-required authorization (EU Data Privacy Directive in the EU) obtained from the subject prior to performing any protocol-related procedures, including screening evaluations. Age ≥ 18 years at time of study entry. Body weight > 30 kg. Multinodular or large, solitary HCC, not eligible for resection or local ablation. Histologically confirmed diagnosis of HCC. Scheduled to receive locoregional therapy as standard of care. At least one measurable site of disease as defined by RECIST 1.1criteria with spiral CT scan or MRI. No prior systemic anti-cancer therapy. Child-Pugh A. Performance status (PS) ≤ 1 (ECOG scale). Life expectancy of at least 12 weeks. Adequate blood count, liver-enzymes, and renal function: Hemoglobin ≥ 9.0 g/dL, absolute neutrophil count ANC ≥1.5 (or 1.0) x (> 1500 per mm^3), platelets ≥100 (or 75) x 10^9/L (>75,000 per mm^3); Serum bilirubin ≤1.5 x institutional upper limit of normal (ULN); AST (SGOT), ALT (SGPT) ≤ 2.5 x institutional ULN unless liver metastases are present, in which case it must be ≤5x ULN; International normalized ratio (INR) ≤ 1.25. Albumin ≥ 31 g/dL. Measured creatinine clearance (CL) >40 mL/min or Calculated creatinine clearance CL>40 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance. Female patients with reproductive potential must have a negative urine or serum pregnancy test within 7 days prior to start of trial and must use two effective forms of contraception if sexually active. Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year. Men receiving IMP and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 7 months after the last dose of investigational products (Durvalumab and Tremelimumab). Women who are not of childbearing potential (i.e. who are postmenopausal or surgically sterile) as well as azoospermic men do not require contraception). If patient has concurrent Hepatitis B virus (HBV) or Hepatitis C virus (HCV) infection, meets the following criteria: Patients with HBV or HCV infection should be monitored for viral levels during study participation; Patients with detectable hepatitis B surface antigen (HBsAg) or detectable HBV DNA should have HBV DNA < 100 IU/ml and should be managed per local treatment guidelines. Controlled (treated) hepatitis B subjects will be allowed if they started treatment at the time point of enrollment into the study by the latest and treatment is continued during study participation and for ≥ 6 months after end of study treatment; HCV patients with advanced HCC are mostly not treated for their HCV infection. However, patients treated for HCV are considered suitable for inclusion if antiviral therapy has been completed prior to first administration of study drug. Subject is willing and able to comply with the protocol for the duration of the study including Exclusion Criteria: Diffuse HCC or presence of vascular invasion or extrahepatic spread with the following exception: o Invasion of a segmental portal vein or hepatic veins. Patients with advanced liver disease as defined below: o liver cirrhosis with stage Child Pugh B and C. Any contraindications for hepatic embolization procedures: Known hepatofugal blood flow; Known porto-systemic shunt; Impaired clotting test (platelet count < 70 x 10^9/L, INR > 1.25); Renal failure/insufficiency requiring hemo-or peritoneal dialysis; Known severe atheromatosis; Total thrombosis or total invasion of the main branch of the portal vein. Locoregional therapies ongoing or completed < 4 weeks prior to the baseline scan. History of cardiac disease: Congestive heart failure > New York Heart Association (NYHA) class 2; Active coronary artery disease (CAD) (myocardial infarction ≥ 6 months prior to study entry is allowed); Cardiac arrhythmias (Grade > 2 NCI-CTCAE Version 5.0) which are poorly controlled with anti-arrhythmic therapy or requiring pace maker; Uncontrolled hypertension; Clinically significant gastrointestinal bleeding within 4 weeks prior to start of study drug. Thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within the 6 months prior to the first dose of study drug with the exception of thrombosis of a segmental portal vein. Prior, systemic anti-cancer therapy, radiotherapy administered < 4 weeks prior to study entry, endocrine- or immunotherapy or use of other investigational agents. Current or prior use of immunosuppressive medication within 14 days before the first dose of Durvalumab or Tremelimumab. The following are exceptions to this criterion: Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection) Systemic corticosteroids at physiologic doses not to exceed <<10 mg/day>> of prednisone or its equivalent Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication) Receipt of live attenuated vaccine within 30 days prior to the first dose of IP. Note: Patients, if enrolled, should not receive live vaccine whilst receiving IP and up to 30 days after the last dose of IP. Major surgery within 4 weeks of starting the study and patients must have recovered from effects of major surgery. Patients with second primary cancer, except adequately treated basal skin cancer or carcinoma in-situ of the cervix, unless curatively treated and disease-free for 3 years or longer. Any co-existing medical condition that in the investigator's judgement will substantially increase the risk associated with the patient's participation in the study. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C, Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA History of allogenic organ transplantation. Psychiatric disorders or altered mental status precluding understanding of the informed consent process and/or compliance with the study protocol. Symptomatic brain metastases. A scan to confirm the absence of brain metastases is required in the presence of corresponding symptoms. Pregnant or breast-feeding women. Immunocompromised patients, e.g. patients who are known to be serologically positive for human immunodeficiency virus (HIV). Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc.]). The following are exceptions to this criterion: Patients with vitiligo or alopecia Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement Any chronic skin condition that does not require systemic therapy Patients without active disease in the last 5 years may be included but only after consultation with the study physician Patients with celiac disease controlled by diet alone Known allergy or hypersensitivity to any of the IMPs or any of the constituents of the product. Is currently participating or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment. Patient who has been incarcerated or involuntarily
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Arndt Vogel, Prof. Dr.
Phone
+49 511 532 9590
Email
vogel.arndt@mh-hannover.de
First Name & Middle Initial & Last Name or Official Title & Degree
Johanna Riedel, Dr.
Phone
+49 69 7601 4635
Email
riedel.johanna@ikf-khnw.de
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Salah-Eddin Al-Batran, Prof. Dr.
Organizational Affiliation
Institut für Klinische Krebsforschung IKF GmbH
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Arndt Vogel, Prof. Dr.
Organizational Affiliation
Hannover Medical School
Official's Role
Principal Investigator
Facility Information:
Facility Name
Universitätsklinikum Bonn
City
Bonn
ZIP/Postal Code
53127
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Maria Gonzalez-Carmona, PD Dr.
Facility Name
Universitätsklinikum Essen
City
Essen
ZIP/Postal Code
45147
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hartmut Schmidt, Prof.Dr.
Facility Name
Universitätsklinikum Freiburg
City
Freiburg
ZIP/Postal Code
79106
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michael Schultheiss, Dr.
Facility Name
Medizinische Hochschule Hannover
City
Hannover
ZIP/Postal Code
30625
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Arndt Vogel, Prof. Dr.
Facility Name
Universitätsklinikum Jena
City
Jena
ZIP/Postal Code
07747
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Udo Lindig, Dr.
Facility Name
Universitätsklinikum Köln
City
Köln
ZIP/Postal Code
50937
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dirk Waldschmidt, Dr.
Facility Name
Universtitätsklinikum Schleswig-Holstein
City
Lübeck
ZIP/Postal Code
23538
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jens Marquardt, Prof. Dr.
Facility Name
Klinikum rechts der Isar der Technischen Universität München
City
München
ZIP/Postal Code
81675
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ursula Ehmer, PD Dr.
Facility Name
München Klinik Bogenhausen
City
München
ZIP/Postal Code
81925
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Martin Fuchs, Dr.

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
No IPD will be shared.

Learn more about this trial

Durvalumab and Tremelimumab in Combination With Either Y-90 SIRT or DEB-TACE for Intermediate Stage HCC

We'll reach out to this number within 24 hrs